Redbiotec AG

Redbiotec is a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH Zurich), the company has won several awards, including the renowned W.A. De Vigier Award. The company is successful in producing key proteins and genetic materials for biopharma and food industry thanks to a dedicated scientific team with expertise in multiple disciplines from immunology and microbial engineering to protein engineering. Presently, Redbiotec is involved in the alternative-dairy development. We are using precise fermentation in different expression platforms to recombinantly produce milk proteins, such as caseins, with high yield and their post-translational modifications. We actively evaluate partnering opportunities with the goal of reinforcing our portfolio, and/or to add value to the process developed by our collaboration partners. We welcome strategic partnerships to use our recombinant proteins for animal-free food products and to increase the impact of our technology platforms.

Website

http://www.redbiotec.ch

Externer Link zu Redbiotec AG

Branche

Biotechnologieforschung

Größe

11–50 Beschäftigte

Hauptsitz

Zurich, Zurich

Art

Privatunternehmen

Gegründet

2006

Spezialgebiete

Vaccines, Virus-like particles (VLPs), Biologics, Proteins, Protein complexes, Oncolytic bacteria, Herpes, HSV-2, Gene therapy delivery, Immunotherapy, Oncolytic virus, Immuno-oncology, Pancreatic cancer, Cervical cancer, HPV, Protein engineering, Microbial engineering und Therapeutic vaccine